DelveInsight’s “Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market Insights, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of mRNA-based vaccines and therapeutics, historical and forecasted epidemiology, as well as market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the mRNA Vaccines and Therapeutics Market with DelveInsight’s In-Depth Report @ Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market Size

Key Takeaways from the mRNA Vaccines and Therapeutics Market Report

• In January 2026 – Arcturus Therapeutics Holdings Inc. continued advancing its cystic fibrosis pipeline, building on the successful approval of the Clinical Trial Application (CTA) for ARCT-032, its inhaled investigational mRNA therapy. The candidate has progressed through early-stage clinical development and remains a key component of the company’s strategy to address unmet needs in cystic fibrosis and other rare respiratory diseases.

• In January 2026 – CSL Limited, through its subsidiary CSL Seqirus, continued to leverage its global collaboration and licensing partnership with Arcturus Therapeutics Holdings Inc.. The agreement provides access to Arcturus’ self-amplifying mRNA (sa-mRNA) vaccine platform, supporting the development of next-generation vaccine candidates and strengthening CSL Seqirus’ capabilities in innovative vaccine technologies.

• The leading mRNA Vaccines and Therapeutics companies include Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc., and others.

• Technological advancements in mRNA platforms — including improved delivery systems and enhanced stability — are primary drivers of market expansion.

• Rising demand for rapid vaccine development (e.g., COVID-19, influenza) and personalized cancer immunotherapies is fueling market growth globally.

• The Global mRNA Vaccines and Therapeutics market in the 7MM is expected to witness major change during the study period 2020–2034.

• Supportive government initiatives, grants, and public-private partnerships are enhancing research, development, and commercialization of mRNA-based products.

• Strategic collaborations between biotech companies, pharmaceutical firms, and research institutions are accelerating product development and market penetration.

• Streamlined regulatory approvals and increasing market access are encouraging broader adoption and global market growth.

Stay ahead in the mRNA Vaccines and Therapeutics Market with DelveInsight’s Strategic Report @ Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market Outlook

mRNA Vaccines and Therapeutics Epidemiology Segmentation in the 7MM

• Total mRNA Vaccines and Therapeutics Market Size

• Market Size by Therapies

• Market Size by Class

• mRNA Treatment Market

• mRNA Pipeline Analysis

mRNA Vaccines and Therapeutics Pipeline Analysis

Pfizer Inc. / BioNTech SE — mRNA Vaccine Platform: Pioneered mRNA vaccine technology with the COVID-19 vaccine and now expanding into influenza, oncology, and other infectious diseases using advanced lipid nanoparticle (LNP) delivery systems.

Moderna, Inc. — mRNA-1283 / mRNA Therapeutics: Next-generation mRNA platform targeting respiratory diseases, cancer immunotherapies, and rare diseases, with a focus on improved lipid nanoparticle delivery and self-amplifying mRNA technologies.

GSK plc. — mRNA Vaccine Programs: Developing mRNA-based vaccines and therapeutics across infectious disease and oncology indications through strategic collaborations and in-house capabilities.

CureVac SE — mRNA Technology Platform: Proprietary mRNA technology platform with a pipeline spanning prophylactic vaccines, cancer therapies, and molecular therapy for rare diseases.

Daiichi Sankyo — mRNA Oncology Programs: Oncology-focused mRNA therapeutics pipeline leveraging mRNA for next-generation cancer treatment in combination with antibody-drug conjugate approaches.

Arcturus Therapeutics — LUNAR mRNA Platform: Proprietary lipid-mediated delivery platform (LUNAR) for mRNA medicines, targeting liver diseases, respiratory conditions, and vaccines.

Sanofi — mRNA Vaccines & Therapeutics: Investing in mRNA vaccine and therapeutic platforms through partnerships and acquisitions to build out a next-generation immunology pipeline.

Boehringer Ingelheim — mRNA Therapeutics: Developing mRNA-based therapeutic applications with focus on respiratory and metabolic diseases.

mRNA Vaccines and Therapeutics Market Insights

The current mRNA treatment landscape includes prophylactic vaccines (infectious disease), therapeutic cancer vaccines, personalized cancer immunotherapies, and mRNA-based protein replacement therapies for rare and metabolic diseases.

mRNA technology has emerged as a transformative pillar of modern medicine — particularly following the success of COVID-19 vaccines — demonstrating the platform’s capacity for rapid development, scalability, and broad applicability across disease areas.

The competitive landscape is highly dynamic and innovation-driven, with leading players advancing lipid nanoparticle delivery systems, self-amplifying mRNA, circular mRNA, and next-generation personalized cancer vaccines.

Strategic collaborations, licensing agreements, and mergers and acquisitions are common as companies seek to strengthen pipelines and access novel delivery platforms. Public-private partnerships, government funding, and regulatory fast-track designations are further accelerating market development.

The expected introduction of emerging therapies with improved efficacy, greater disease awareness, and higher diagnosis rates are likely to boost market growth across the 7MM throughout the forecast period.

Get In-Depth Knowledge on mRNA Vaccines and Therapeutics Market Trends and Forecasts with DelveInsight @https://www.delveinsight.com/sample-request/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

mRNA Vaccines and Therapeutics Market Outlook

mRNA vaccines and therapeutics represent a paradigm shift in medicine — harnessing the body’s own cellular machinery to produce therapeutic proteins, antigens, or immune modulators. Unlike conventional biologics, mRNA does not alter the genome and can be designed, synthesized, and scaled rapidly.

Well-established mRNA delivery platforms include lipid nanoparticles (LNPs), polymeric nanoparticles, and emerging self-amplifying mRNA technologies. The pipeline is highly robust with potential therapies under investigation across oncology, infectious disease, rare genetic conditions, and autoimmune disorders. The treatment space is expected to experience a significant market impact during the forecast period. Market growth may be moderated by therapy failures or discontinuations, manufacturing scale-up challenges, cold-chain distribution requirements, high pricing, and market access and reimbursement barriers.

Scope of the mRNA Vaccines and Therapeutics Market Report

• Coverage: 7MM

• Study Period: 2020–2034

• Forecast Period: 2023–2034

• Key Companies: Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, CureVac SE, Sanofi, Kernal Biologics Inc., and others

• Key Therapies: mRNA COVID-19 vaccines, mRNA influenza vaccines, personalized cancer mRNA vaccines, mRNA protein replacement therapies, and others

• Market Access & Reimbursements, Unmet Needs and Perspectives

• SWOT Analysis and KOL Views

Unlock Strategic Insights with DelveInsight’s Comprehensive mRNA Market Report @ Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market Drivers and Barriers

Table of Contents

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis

4. Market Overview

5. Disease Background and Overview

6. Patient Journey

7. Epidemiology and Patient Population

8. Treatment Landscape

9. Unmet Needs

10. Key Clinical Endpoints

11. Marketed Products

12. Emerging Therapies

13. Seven Major Markets (7MM) Analysis

14. Market Outlook (2020–2034)

15. Access and Reimbursement Overview

16. KOL Perspectives

17. Market Drivers

18. Market Barriers

19. Research Methodology

20. Appendix

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/